12.81

3.47% -0.46

Assembly Biosciences Inc (ASMB)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Assembly Biosciences Inc stock is currently priced at $12.81, with a 24-hour trading volume of 20,698. It has seen a -3.47% decreased in the last 24 hours and a -5.11% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $13.15 pivot point. If it approaches the $12.46 support level, significant changes may occur.

Previous Close:

$13.27

Open:

$13.28

24h Volume:

20,698

Market Cap:

$70.23M

Revenue:

Net Income/Loss:

$-61.23M

P/E Ratio:

-7.8589

EPS:

-1.63

Net Cash Flow:

$22.49M

1W Performance:

-4.12%

1M Performance:

-5.11%

6M Performance:

+1,372%

1Y Performance:

+1,144%

1D Range:

$12.81

$13.28

52W Range:

$0.641

$15.19

Assembly Biosciences Inc Stock (ASMB) Company Profile

Name

Assembly Biosciences Inc

Sector

Healthcare (1210)

Industry

Biotechnology (681)

Phone

833 509 4583

Address

331 Oyster Point Boulevard, Fourth Floor, South San Francisco

Employee

102

Twitter

Next Earnings Date

2024-05-29

Latest SEC Filings

ASMB's Discussions on Twitter

Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-13-21	Initiated	H.C. Wainwright	Neutral
Sep-02-21	Downgrade	William Blair	Outperform → Mkt Perform
Mar-23-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-06-20	Downgrade	Jefferies	Buy → Hold
Oct-19-20	Initiated	Truist	Buy
Oct-16-19	Initiated	Mizuho	Buy
Nov-19-18	Initiated	Leerink Partners	Outperform
Oct-08-18	Upgrade	B. Riley FBR	Neutral → Buy
Aug-08-18	Initiated	Robert W. Baird	Outperform
Apr-13-18	Downgrade	Chardan Capital Markets	Buy → Neutral
Jan-05-18	Initiated	B. Riley FBR, Inc.	Neutral
Nov-08-17	Initiated	Jefferies	Buy
May-30-17	Initiated	Chardan Capital Markets	Buy

View All

Assembly Biosciences Inc Stock (ASMB) Latest News

Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?

Zacks Investment Research

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

GlobeNewswire Inc.

Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

Benzinga

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Assembly Biosciences Inc Stock (ASMB) Financials Data

Assembly Biosciences Inc (ASMB) Net Income 2024

ASMB net income (TTM) was -$61.23 million for the quarter ending December 31, 2023, a +34.23% increase year-over-year.

Assembly Biosciences Inc (ASMB) Cash Flow 2024

ASMB recorded a free cash flow (TTM) of $22.49 million for the quarter ending December 31, 2023, a +126.59% increase year-over-year.

Assembly Biosciences Inc (ASMB) Earnings per Share 2024

ASMB earnings per share (TTM) was -$13.52 for the quarter ending December 31, 2023, a +41.57% growth year-over-year.

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.